News | Prostate Cancer | November 02, 2015

First Results Reported for Prostate Cancer Targeted Brachytherapy Using CivaString

Palladium-based source offers positive outcomes with more highly targeted radiation

CivaTech Oncology, CivaString, prostate brachytherapy, 103Pd radiation source, ASTRO 2015

Image courtesy of Business Wire

November 2, 2015 — CivaTech Oncology Inc. has developed a new U.S. Food and Drug Administration (FDA)-cleared radiation source. The CivaString source features 103Pd (palladium) along the full length of the device, which is contained using low-Z polymers. Low-dose-rate brachytherapy historically relies on a loose or stranded isotope whose dosimetry is characterized as point sources. A polymer-encapsulated 103Pd source with a unique linear radioactive distribution provides a useful refinement for prostate brachytherapy.

An abstract and poster titled “First Report of a New 103Pd Line Source for Prostate Brachytherapy” presenting results from the first 14 patients in an ongoing clinical study was submitted and accepted at the American Society for Radiation Oncology (ASTRO) 2015 conference in San Antonio, and published in ASTRO’s International Journal of Radiation Oncology. Radiation oncologists David Beyer, M.D., and Richard Stock, M.D., implanted patients in Arizona and New York.

The abstract concluded: “An initial experience with this new line source is presented. Excellent implants across a range of gland sizes were accomplished. Prostate volume changes were minimal suggesting minimal swelling using the chosen needles and ‘strings.’ Good dosimetry is achieved for both preplans and eventual implants. Using a line source, the number of needles required per patient is less than that reported with standard brachytherapy sources. Intraoperative ease of use is good.”

This study is ongoing with 26 total patients and is expected to conclude at the end of 2015, at which time a full report will be published. Additionally a five-year, 150-patient registry has begun to fully demonstrate how the advanced polymer technology benefits patients when used to treat prostate cancer.

For more information:

Related Content

Turkish Hospital Begins MR-Guided Radiation Therapy With Viewray MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | September 21, 2018
ViewRay Inc. announced that Acibadem Maslak Hospital in Istanbul, Turkey has begun treating patients with ViewRay's...
Exact Imaging Partners to Improve Prostate Cancer Detection With Artificial Intelligence
News | Prostate Cancer | September 19, 2018
Exact Imaging, makers of the ExactVu micro-ultrasound platform, has partnered with U.K.-based Cambridge Consultants to...
Amar Kishan, M.D.

Amar Kishan, M.D.

News | Prostate Cancer | September 11, 2018
UCLA researchers have discovered that a combination of high doses of...
Videos | Radiation Therapy | September 07, 2018
A discussion with Ehsan Samei, Ph.D., DABR, FAAPM, FSPIE, director of the Duke University Clinical Imaging Physics Gr
Boston Scientific to Acquire Augmenix Inc.
News | Patient Positioning Radiation Therapy | September 07, 2018
Boston Scientific has entered into a definitive agreement to acquire Augmenix Inc., a privately-held company which has...

Image courtesy of IBA

Feature | Radiation Oncology | September 07, 2018 | By Jeff Zagoudis
According to the latest statistics from the American Cancer Society (ACS), almost 165,000 new cases of prostate cancer...
Non-Canonical Strategy May Improve Cancer Radiotherapy
News | Radiation Therapy | August 29, 2018
August 29, 2018 — Although the success or failure of...
Videos | Treatment Planning | August 28, 2018
A discussion with...
Sponsored Content | Webinar | Radiation Therapy | August 28, 2018
Respiratory tumor motion often complicates the delivery of precision radiation treatment.
Tsuyama Chuo Proton Beam Center Treats First Patients With RayStation
News | Treatment Planning | August 27, 2018
Tsuyama Chuo Hospital in Okayama Prefecture, southwest Japan, has commenced clinical use of RayStation to plan pencil...